Vinorelbine--a clinical review.
作者信息
Gregory R K, Smith I E
机构信息
Department of Medicine, Royal Marsden NHS Trust and Institute of Cancer Research, London, UK.
出版信息
Br J Cancer. 2000 Jun;82(12):1907-13. doi: 10.1054/bjoc.2000.1203.
Abstract
摘要
相似文献
1
Vinorelbine--a clinical review.长春瑞滨——临床综述。
Br J Cancer. 2000 Jun;82(12):1907-13. doi: 10.1054/bjoc.2000.1203.
2
[Vinorelbine for non-small cell lung cancer].长春瑞滨用于非小细胞肺癌
Nihon Rinsho. 2002 May;60 Suppl 5:353-8.
3
Acute lung injury associated with vinorelbine.与长春瑞滨相关的急性肺损伤。
J Clin Oncol. 2006 Apr 20;24(12):1952-3. doi: 10.1200/JCO.2005.03.0023.
4
Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.多西他赛维持治疗晚期非小细胞肺癌反应者的随机研究。 （你提供的原文和译文似乎不匹配，根据你提供的原文，正确译文应该是：晚期非小细胞肺癌反应者中长春瑞滨维持治疗的随机研究。 ）
J Natl Cancer Inst. 2005 Apr 6;97(7):499-506. doi: 10.1093/jnci/dji096.
5
MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.多药耐药基因1单核苷酸多态性预测非小细胞肺癌患者对长春瑞滨为主的化疗的反应。
Respiration. 2008;75(4):380-5. doi: 10.1159/000108407. Epub 2007 Sep 12.
6
Adynamic ileus in a patient with non-small-cell lung cancer after treatment with vinorelbine.一名非小细胞肺癌患者在接受长春瑞滨治疗后发生麻痹性肠梗阻。
Am J Med. 1996 Dec;101(6):658-9. doi: 10.1016/S0002-9343(97)89428-4.
7
Vinorelbine: an update and review of activity.
Clin Oncol (R Coll Radiol). 1996;8(6):353-7. doi: 10.1016/s0936-6555(96)80075-6.
8
Vinorelbine tartrate: a promising new chemotherapeutic agent.
J Intraven Nurs. 1996 Jan-Feb;19(1):16-27.
9
10
[Navelbine. Current and perspective aspects. International congress of Biarritz (November 1989)].
Bull Cancer. 1990;77(8):841-5.
引用本文的文献
1
Efficacy and safety of metronomic oral vinorelbine and its combination therapy as second- and later-line regimens for advanced non-small-cell lung cancer: a retrospective analysis.节拍口服长春瑞滨及其联合治疗方案作为晚期非小细胞肺癌二线及以上治疗方案的疗效和安全性：回顾性分析。
Clin Transl Oncol. 2024 Dec;26(12):3202-3210. doi: 10.1007/s12094-024-03543-z. Epub 2024 Jun 9.
2
What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?横纹肌肉瘤的最佳全身治疗选择是什么？
Curr Treat Options Oncol. 2024 Jun;25(6):784-797. doi: 10.1007/s11864-024-01206-3. Epub 2024 May 16.
3
Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.依维莫司与长春瑞滨协同作用抑制肝癌生长。
Int J Mol Sci. 2023 Dec 19;25(1):17. doi: 10.3390/ijms25010017.
4
Research Progress of Indole Alkaloids: Targeting MAP Kinase Signaling Pathways in Cancer Treatment.吲哚生物碱的研究进展：针对癌症治疗中的丝裂原活化蛋白激酶信号通路
Cancers (Basel). 2023 Nov 7;15(22):5311. doi: 10.3390/cancers15225311.
5
Modern treatment strategies in pediatric oncology and hematology.儿科肿瘤学和血液学的现代治疗策略。
Discov Oncol. 2023 Jun 14;14(1):98. doi: 10.1007/s12672-023-00658-7.
6
Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges.长春花生物碱作为一种潜在的癌症治疗药物：最新进展与未来挑战
3 Biotech. 2023 Jun;13(6):211. doi: 10.1007/s13205-023-03636-6. Epub 2023 May 24.
7
Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.肺泡横纹肌肉瘤在复发性/难治性疾病患者中的长春瑞滨缓解率优于胚胎性横纹肌肉瘤：一项荟萃分析。
Cancer Med. 2023 May;12(9):10222-10229. doi: 10.1002/cam4.5749. Epub 2023 Apr 4.
8
NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs.NKp44 衍生肽与靶向治疗药物联合使用可刺激抗肿瘤疗效。
Int J Mol Sci. 2022 Nov 14;23(22):14054. doi: 10.3390/ijms232214054.
9
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.基于模型的群体药代动力学分析：药物遗传学对儿科患者口服长春瑞滨暴露变异性的影响。
Cancer Chemother Pharmacol. 2022 Jul;90(1):29-44. doi: 10.1007/s00280-022-04446-y. Epub 2022 Jun 25.
10
Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine.生物碱的抗癌潜力：重点关注秋水仙碱、长春碱、长春新碱、长春地辛、长春瑞滨和长春胺。
Cancer Cell Int. 2022 Jun 2;22(1):206. doi: 10.1186/s12935-022-02624-9.
本文引用的文献
1
Antitumor principles derived from Vinca rosea Linn. I. Vincaleukoblastine and leurosine.从长春花中提取的抗肿瘤原理。I. 长春新碱和长春质碱。
Cancer Res. 1960 Aug;20:1016-22.
2
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.抗微管蛋白药物对细胞凋亡信号转导通路的影响：综述
Cancer Chemother Pharmacol. 1999;44(5):355-61. doi: 10.1007/s002800050989.
3
Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.
Ann Oncol. 1999 Apr;10(4):397-402. doi: 10.1023/a:1008364222793.
4
A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.一项针对难治性上皮性卵巢癌的长春瑞滨静脉注射每日3次方案的I期研究。
Gynecol Oncol. 1998 Sep;70(3):404-9. doi: 10.1006/gyno.1998.5130.
5
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.比较顺铂与顺铂加长春瑞滨治疗晚期非小细胞肺癌的随机试验：一项西南肿瘤协作组研究
J Clin Oncol. 1998 Jul;16(7):2459-65. doi: 10.1200/JCO.1998.16.7.2459.
6
Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).顺铂-长春地辛-丝裂霉素（MVP）方案与顺铂-异环磷酰胺-长春瑞滨（PIN）方案及卡铂-长春瑞滨（CaN）方案治疗晚期非小细胞肺癌（NSCLC）的疗效比较：一项FONICAP随机II期研究。意大利肺癌工作组（FONICAP）
Br J Cancer. 1998 Jun;77(12):2367-70. doi: 10.1038/bjc.1998.393.
7
Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole.卡铂联合长春瑞滨，一种耐受性良好且有效的治疗广泛期小细胞肺癌的新方案：一项II期研究。中南岛屿肿瘤协作组。
J Clin Oncol. 1998 Apr;16(4):1414-9. doi: 10.1200/JCO.1998.16.4.1414.
8
A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung.异环磷酰胺与长春瑞滨治疗晚期非小细胞肺癌的综述。
Semin Oncol. 1998 Feb;25(1 Suppl 2):8-14.
9
Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix.
J Clin Oncol. 1998 Mar;16(3):1094-8. doi: 10.1200/JCO.1998.16.3.1094.
10
Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study.卡铂和长春瑞滨治疗晚期非小细胞肺癌：一项多中心II期研究。
Am J Clin Oncol. 1998 Feb;21(1):67-71. doi: 10.1097/00000421-199802000-00015.
Zotero 插件